HFSA Annual Scientific Meeting 2026

A post hoc ATTRibute-CM analysis examined cardiovascular outcomes and changes in NT-proBNP among women receiving acoramidis.

A post hoc ATTRibute-CM analysis examined whether the Day 28 eGFR dip affected acoramidis outcomes through 30 months.

A retrospective study compared clinical outcomes after patients with ATTR-CM started acoramidis or tafamidis.

A post hoc ATTRibute-CM analysis examined days lost to death or cardiovascular hospitalization with acoramidis versus placebo.

In a post hoc analysis of 611 ATTRibute-CM participants, acoramidis was associated with a 41% lower risk of first outpatient worsening heart failure than placebo over 30 months.

A post hoc ATTRibute-CM analysis found less deterioration in health status and quality of life with acoramidis versus placebo.

In a post hoc ATTRibute-CM analysis, patient-reported heart failure health status recovered after a first cardiovascular-related hospitalization among acoramidis recipients, while continuing to decline...

The prospective, single-arm ASCEND-ATTR study is enrolling adults with transthyretin amyloid cardiomyopathy (ATTR-CM) to assess whether cardiac magnetic resonance imaging shows improved left ventricular...

In a post hoc analysis of 611 ATTRibute-CM participants, 30-month survival was lower among those with more cardiovascular-related hospitalizations, across pooled acoramidis and placebo groups.

In a retrospective study of 132 patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who switched from tafamidis to acoramidis, 49.2% had a cardiovascular-related hospital or emergency department...